Final Survival Analysis: Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study – Journal of Clinical Oncology

Commentary on Twitter

Just in JCO @ASCO ?Glad to share final OS data from TITAN trial after ~4 yrs of follow up: unprecedented OS benefit with APALUTAMIDE/ APA after adjusting for crossover from placebo?48% reduction in risk of death with APA, HR=0.52 ?https://t.co/9ZCoXsTE6x @oncoalert @urotoday pic.twitter.com/FNBFA84DxY

— Neeraj Agarwal (@neerajaiims) April 29, 2021